MIDDLE EAST AND TURKEY HEMOPHILIA TREATMENT MARKET ANALYSIS
Middle East and Turkey Hemophilia Treatment Market- Key Developments
On February 23, 2023, Sanofi S.A., a healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy and indicated for routine prophylaxis, as well as perioperative management (surgery) for adults and children with hemophilia A.
On January 8, 2023, BioMarin Pharmaceutical Inc., a biotechnology company, announced positive results of its ongoing global Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec), an investigational one-time gene therapy for the treatment of adults with severe hemophilia A
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
